323 related articles for article (PubMed ID: 20920855)
1. [Biosimilars: assessment of efficacy, safety and cost].
Domínguez-Gil Hurlé A
Farm Hosp; 2010 Mar; 34 Suppl 1():25-8. PubMed ID: 20920855
[TBL] [Abstract][Full Text] [Related]
2. [Biosimilars].
Krämer I
Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
[TBL] [Abstract][Full Text] [Related]
3. [Biosimilars - Potential, risks and open questions].
Dtsch Med Wochenschr; 2014 Jan; 139(1-2):12-3. PubMed ID: 24551883
[No Abstract] [Full Text] [Related]
4. [Biosimilars: regulatory status for approval].
Herrero Ambrosio A
Farm Hosp; 2010 Mar; 34 Suppl 1():16-8. PubMed ID: 20920853
[TBL] [Abstract][Full Text] [Related]
5. Biosimilars: How Can Payers Get Long-Term Savings?
Mestre-Ferrandiz J; Towse A; Berdud M
Pharmacoeconomics; 2016 Jun; 34(6):609-16. PubMed ID: 26792791
[TBL] [Abstract][Full Text] [Related]
6. Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future.
Grabowski HG; Guha R; Salgado M
Health Aff (Millwood); 2014 Jun; 33(6):1048-57. PubMed ID: 24889955
[TBL] [Abstract][Full Text] [Related]
7. Low-molecular-weight heparin biosimilars: potential implications for clinical practice. Australian Low-Molecular-Weight Heparin Biosimilar Working Group (ALBW).
Nandurkar H; Chong B; Salem H; Gallus A; Ferro V; McKinnon R;
Intern Med J; 2014 May; 44(5):497-500. PubMed ID: 24816308
[TBL] [Abstract][Full Text] [Related]
8. Biosimilars for inflammatory bowel disease: how can healthcare professionals help address patients' concerns?
Gecse KB; Cumming F; D'Haens G
Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):143-155. PubMed ID: 30791783
[TBL] [Abstract][Full Text] [Related]
9. Biosimilars for the management of rheumatoid arthritis: economic considerations.
Gulácsi L; Brodszky V; Baji P; Kim H; Kim SY; Cho YY; Péntek M
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S43-52. PubMed ID: 26395836
[TBL] [Abstract][Full Text] [Related]
10. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
[TBL] [Abstract][Full Text] [Related]
11. Meeting Report: AGA Biosimilars Roundtable.
Howden CW; Lichtenstein GR
Gastroenterology; 2018 Apr; 154(5):e1-e5. PubMed ID: 29510132
[No Abstract] [Full Text] [Related]
12. [The story of biosimilars--chance or threat?].
Woroń J; Kocić I
Pol Merkur Lekarski; 2014 Nov; 37(221):311-5. PubMed ID: 25546996
[TBL] [Abstract][Full Text] [Related]
13. Biosimilars for Immune-Mediated Chronic Diseases in Primary Care: What a Practicing Physician Needs to Know.
Feldman SR; Bagel J; Namak S
Am J Med Sci; 2018 May; 355(5):411-417. PubMed ID: 29753369
[TBL] [Abstract][Full Text] [Related]
14. [Biosimilar filgrastim: from development to record].
García Alfonso P
Farm Hosp; 2010 Mar; 34 Suppl 1():19-24. PubMed ID: 20920854
[TBL] [Abstract][Full Text] [Related]
15. Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation.
Scott BJ; Klein AV; Wang J
J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S123-32. PubMed ID: 24965228
[TBL] [Abstract][Full Text] [Related]
16. Biosimilars: controversies as illustrated by rhGH.
Declerck PJ; Darendeliler F; Góth M; Kolouskova S; Micle I; Noordam C; Peterkova V; Volevodz NN; Zapletalová J; Ranke MB
Curr Med Res Opin; 2010 May; 26(5):1219-29. PubMed ID: 20302553
[TBL] [Abstract][Full Text] [Related]
17. Biosimilars: Implications for Clinical Practice.
Rifkin RM; Peck SR
J Oncol Pract; 2017 Sep; 13(9_suppl):24s-31s. PubMed ID: 28898593
[TBL] [Abstract][Full Text] [Related]
18. Biosimilars in Dermatology - theory becomes reality.
Gerdes S; Mrowietz U; Augustin M; Ralph von Kiedrowski ; Enk A; Strömer K; Schön MP; Radtke MA
J Dtsch Dermatol Ges; 2018 Feb; 16(2):150-160. PubMed ID: 29364594
[TBL] [Abstract][Full Text] [Related]
19. The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis.
Yoo DH
Expert Rev Clin Immunol; 2014 Aug; 10(8):981-3. PubMed ID: 24961712
[TBL] [Abstract][Full Text] [Related]
20. Biosimilars in Dermatology: Current Situation (Part I).
Puig L; Carretero G; Daudén E; Ferrándiz C; Marrón SE; Martorell A; Pérez-Suárez B; Rodriguez-Cerdeira C; Ruiz-Villaverde R; Sánchez-Carazo JL; Velasco M;
Actas Dermosifiliogr; 2015 Sep; 106(7):545-9. PubMed ID: 25987472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]